EP2470229B1 - Use of gelled prp (platelet gel) for volumetric breast reconstruction - Google Patents
Use of gelled prp (platelet gel) for volumetric breast reconstruction Download PDFInfo
- Publication number
- EP2470229B1 EP2470229B1 EP10722715.9A EP10722715A EP2470229B1 EP 2470229 B1 EP2470229 B1 EP 2470229B1 EP 10722715 A EP10722715 A EP 10722715A EP 2470229 B1 EP2470229 B1 EP 2470229B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- platelet
- soft tissue
- biological implant
- gel
- platelet gel
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 210000000481 breast Anatomy 0.000 title claims description 42
- 239000007943 implant Substances 0.000 claims description 57
- 210000004623 platelet-rich plasma Anatomy 0.000 claims description 35
- 210000004872 soft tissue Anatomy 0.000 claims description 28
- 206010028980 Neoplasm Diseases 0.000 claims description 23
- 238000000034 method Methods 0.000 claims description 19
- 206010053567 Coagulopathies Diseases 0.000 claims description 16
- 230000035602 clotting Effects 0.000 claims description 16
- 230000008569 process Effects 0.000 claims description 12
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 9
- 230000003416 augmentation Effects 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 9
- 239000012190 activator Substances 0.000 claims description 8
- 239000001110 calcium chloride Substances 0.000 claims description 7
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 7
- 238000012937 correction Methods 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 7
- 229940079593 drug Drugs 0.000 claims description 7
- 230000000735 allogeneic effect Effects 0.000 claims description 6
- 239000003242 anti bacterial agent Substances 0.000 claims description 5
- 229940088710 antibiotic agent Drugs 0.000 claims description 5
- 230000015572 biosynthetic process Effects 0.000 claims description 5
- 150000001875 compounds Chemical class 0.000 claims description 5
- 230000005856 abnormality Effects 0.000 claims description 4
- 239000012071 phase Substances 0.000 claims description 4
- 238000011282 treatment Methods 0.000 claims description 4
- 238000010438 heat treatment Methods 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 229940035676 analgesics Drugs 0.000 claims description 2
- 239000000730 antalgic agent Substances 0.000 claims description 2
- 230000000844 anti-bacterial effect Effects 0.000 claims description 2
- -1 anti-bacterials Substances 0.000 claims description 2
- 230000001093 anti-cancer Effects 0.000 claims description 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 2
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 2
- 238000001816 cooling Methods 0.000 claims description 2
- 238000002955 isolation Methods 0.000 claims description 2
- 239000007791 liquid phase Substances 0.000 claims description 2
- 230000003068 static effect Effects 0.000 claims description 2
- 230000002476 tumorcidal effect Effects 0.000 claims description 2
- 210000001015 abdomen Anatomy 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 description 9
- 230000002980 postoperative effect Effects 0.000 description 8
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 230000009826 neoplastic cell growth Effects 0.000 description 6
- 229920001296 polysiloxane Polymers 0.000 description 6
- 230000003187 abdominal effect Effects 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 4
- 101800003838 Epidermal growth factor Proteins 0.000 description 4
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 4
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 4
- 108090000190 Thrombin Proteins 0.000 description 4
- 102000009618 Transforming Growth Factors Human genes 0.000 description 4
- 108010009583 Transforming Growth Factors Proteins 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 229940116977 epidermal growth factor Drugs 0.000 description 4
- 239000003102 growth factor Substances 0.000 description 4
- 231100000241 scar Toxicity 0.000 description 4
- 238000001356 surgical procedure Methods 0.000 description 4
- 229960004072 thrombin Drugs 0.000 description 4
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 4
- 108010027612 Batroxobin Proteins 0.000 description 3
- 108010049003 Fibrinogen Proteins 0.000 description 3
- 102000008946 Fibrinogen Human genes 0.000 description 3
- 206010052428 Wound Diseases 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 239000003146 anticoagulant agent Substances 0.000 description 3
- 229940127219 anticoagulant drug Drugs 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 229960002210 batroxobin Drugs 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000000919 ceramic Substances 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 230000001815 facial effect Effects 0.000 description 3
- 229940012952 fibrinogen Drugs 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 208000004434 Calcinosis Diseases 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 208000032544 Cicatrix Diseases 0.000 description 2
- 102000009123 Fibrin Human genes 0.000 description 2
- 108010073385 Fibrin Proteins 0.000 description 2
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000003190 augmentative effect Effects 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 159000000007 calcium salts Chemical class 0.000 description 2
- 238000002316 cosmetic surgery Methods 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000006073 displacement reaction Methods 0.000 description 2
- 229950003499 fibrin Drugs 0.000 description 2
- 210000004907 gland Anatomy 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000009607 mammography Methods 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 229910052573 porcelain Inorganic materials 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 230000037390 scarring Effects 0.000 description 2
- 230000037387 scars Effects 0.000 description 2
- 239000000565 sealant Substances 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 229910001220 stainless steel Inorganic materials 0.000 description 2
- 239000010935 stainless steel Substances 0.000 description 2
- 230000017423 tissue regeneration Effects 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 206010052273 Dystrophic calcification Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000035346 Margins of Excision Diseases 0.000 description 1
- 206010062575 Muscle contracture Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 210000003489 abdominal muscle Anatomy 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000001455 anti-clotting effect Effects 0.000 description 1
- 229940030225 antihemorrhagics Drugs 0.000 description 1
- 239000012237 artificial material Substances 0.000 description 1
- 238000001266 bandaging Methods 0.000 description 1
- 238000009412 basement excavation Methods 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000000227 bioadhesive Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000004227 calcium gluconate Substances 0.000 description 1
- 229960004494 calcium gluconate Drugs 0.000 description 1
- 235000013927 calcium gluconate Nutrition 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- NEEHYRZPVYRGPP-UHFFFAOYSA-L calcium;2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Ca+2].OCC(O)C(O)C(O)C(O)C([O-])=O.OCC(O)C(O)C(O)C(O)C([O-])=O NEEHYRZPVYRGPP-UHFFFAOYSA-L 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229960003326 cloxacillin Drugs 0.000 description 1
- LQOLIRLGBULYKD-JKIFEVAISA-N cloxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=CC=CC=C1Cl LQOLIRLGBULYKD-JKIFEVAISA-N 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 208000006111 contracture Diseases 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000003748 differential diagnosis Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000012213 gelatinous substance Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 208000004396 mastitis Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002324 minimally invasive surgery Methods 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000010118 platelet activation Effects 0.000 description 1
- 230000018127 platelet degranulation Effects 0.000 description 1
- 229940071643 prefilled syringe Drugs 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000002278 reconstructive surgery Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229960003766 thrombin (human) Drugs 0.000 description 1
- 239000003634 thrombocyte concentrate Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000037314 wound repair Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
- A61L27/227—Other specific proteins or polypeptides not covered by A61L27/222, A61L27/225 or A61L27/24
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/402—Anaestetics, analgesics, e.g. lidocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
- A61L2300/406—Antibiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/41—Anti-inflammatory agents, e.g. NSAIDs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/416—Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
Definitions
- the present invention relates to the field of reconstruction and augmentation of soft tissue, particularly breast tissue.
- Synthetic breast implants or autologous reconstruction i.e. reconstruction using the patient's own tissue are used for the reconstruction of breasts subjected to tumorectomy or mastectomy or for breast augmentation.
- the main types of artificial implants consist of a silicone capsule filled with silicone gel or saline solution.
- Combined implants have also been disclosed in the literature, such as that disclosed in EP-A-797460 , which uses matrices seeded with cells, preferably muscle cells.
- abdominal adipose skin and tissue and part of the straight abdominal muscles are normally used.
- latissimus dorsi musculocutaneous flap tissue has also been used.
- Platelets play a basic role in the wound repair process, regardless of their aetiology. When a wound occurs, the platelets become activated and release diverse growth factors, such as PDGF (platelet-derived growth factor), EFT (epidermal growth factor) and TGF (transforming growth factor), which converts fibrinogen into fibrin, forming a cross-linking that finally gives rise to a clot.
- PDGF platelet-derived growth factor
- EFT epidermatitis growth factor
- TGF transforming growth factor
- a clotting cascade activator such as an excess of calcium ions (calcium chloride), thrombin, batroxobin, etc.
- platelet gel is widely used in dental and oral and maxillofacial surgery, where it is used basically for bone implantation and regeneration. It is also applied to chronic wounds, ulcers and soft tissues (such as tendons and ligaments). A layer is generally spread over the wound bed to aid healing. Its use in facial plastic surgery and breast augmentation and reduction operations as a sealant and haemostatic agent has been disclosed, where it reduced the need for drainage and compressive bandaging as well as the incidence of complications ( Acta Dermatoven APA Vol. 16, 207, No. 4 ).
- the autologous platelet gel can be moulded into a geometric, rectangular, conical or roller shape to temporarily fill, by way of a plug, cavities due to dental extraction or bone cavities.
- the gel is prepared from just 6 cm 3 of PRP.
- the problem to be solved by the present invention is the provision of a biological implant to be implanted in a soft tissue, preferably a breast, for reconstruction or augmentation of the volume of said tissue, that will overcome the drawbacks of the state of the art.
- the solution is based on the fact that the present inventors unexpectedly found that the use of conveniently moulded platelet gel allows the re-establishment of soft tissue volume over time (see example 3).
- the inventors verified this upon introduction into a cavity produced by tumorectomy in a breast, obtaining good results even using large volumes, for example 250 cm 3 , so that it can be used by way of a biological implant such as a breast implant.
- the present inventors have achieved the volumetric substitution of removed tissue using the platelet gel, favoring internal scarring and improving the aesthetical result without increasing surgical morbidity, as well as augmenting breast volume.
- the disclosure relates to the use of a platelet gel for preparing a a biological implant to be implanted in a soft tissue for reconstruction, augmentation or correction of abnormalities in the size and shape of said soft tissue, characterized in that said biological implant comprises a platelet gel.
- this aspect of the disclosure can be worded as platelet gel for use as a biological implant to be implanted in a soft tissue for reconstruction, augmentation or correction of abnormalities in the size and shape of said soft tissue.
- the first aspect of the invention relates to a biological implant for soft tissue comprising a platelet gel according to the set of claims
- a second aspect of the invention relates to a kit for preparing a biological implant according to the present invention, comprising
- a third aspect of the invention relates to a process for preparing the biological implant, in accordance with the present invention, comprising the following steps:
- a fourth aspect of the invention relates to a biological implant for soft tissue for use according to the set of claims.
- platelet gel as disclosed herein, is particularly advantageous in tumorectomy and mastectomy operations:
- Platelet gel is obtained from platelet-rich plasma (PRP) whereto a clotting process-activating substance (for example, calcium chloride) is added.
- a clotting process-activating substance for example, calcium chloride
- PRP as used herein, is understood to be a concentration of platelets greater than the concentration in peripheral blood suspended in a plasma solution. PRP typically has a minimum platelet count of 7.5 x 10 5 - 1 x 10 6 per ⁇ L.
- Bio implant as used herein, is understood to be a product of substantially biological origin for the replacement or augmentation of a missing or imperfect part of the body.
- the platelet dosage required for preparing the platelet gel can be obtained by means of plateletpheresis.
- Plateletpheresis comprises extraction and separation of blood into its different components by centrifugation at different speeds for the purpose of obtaining platelet-rich plasma (PRP).
- PRP platelet-rich plasma
- PRP can be obtained from the same patient whom the gel (autologous platelet gel) will be implanted or from a healthy allogeneic donor.
- the gel autologous platelet gel
- the platelets are obtained from a healthy allogeneic donor, optionally related to the patient.
- Plateletpheresis can be carried out, for example, using the HaemoneticsTM MCS+ cell separator or Medtronic Inc.'s MagellanTM Autologous Platelet Separation System.
- an anticoagulant is added preferably based on citric acid, such as ACD-A (citric acid, sodium citrate and dextrose).
- citric acid such as ACD-A (citric acid, sodium citrate and dextrose).
- PRP is required to have a minimum platelet count of 7.5 x 10 5 - 1 x 10 6 per ⁇ L.
- the PRP When the PRP is obtained from an allogeneic donor it is preferably treated by irradiation to deactivate any existing viral material or residual leukocyte. This treatment can be carried out during any stage of the gel preparation process.
- the PRP is activated by adding a clotting activator, which is understood to be a substance capable of restoring anti-clotting activity, such as calcium chloride or other calcium salt which acts in a similar way, such as calcium gluconate or calcium carbonate.
- a clotting activator which is understood to be a substance capable of restoring anti-clotting activity, such as calcium chloride or other calcium salt which acts in a similar way, such as calcium gluconate or calcium carbonate.
- calcium chloride is added as a 105 by weight aqueous solution.
- clotting activators can also be used, including thrombin or batroxobin, by heating the mixture at 37oC.
- the platelet gel can also be obtained by means of the processes disclosed in literature, such as those disclosed in EP-B-1239895 , which use batroxobin instead of thrombin.
- the PRP volume to be used is determined based on the final volume to be augmented or restored. Preferably, a correction factor comprised between 1.6 and 2.2 is applied.
- the mixture is allowed to clot in a sterilised mould having adequate dimensions.
- the mould can be made, for example, of ceramic, plastic, silicone glass or stainless steel. Preferably, it is allowed to clot in a sterile porcelain or stainless steel receptacle. More preferably, a porcelain mould is used.
- the shape of the mould in general is such that the resulting gel adopts the desired shape of the implant.
- the mould is preferably formed in the shape of a round concave receptacle with a volume comprised between 75 and 700 cm3.
- the mould has a substantially semispherical shape.
- the shape of the mould is such that the resulting gel takes the form of a breast implant with different volumes.
- the platelet gel for implantation has a volume comprised between 25 and 600 cm3.
- Formation of the gel is fast, generally being formed in less than fifteen minutes.
- the platelet gel can optionally be used to release drugs such as antibiotics, anti-bacterials, analgesics, anti-inflammatories, anti-cancer compounds and tumoricidal or tumor static compounds. These compounds can be added to the PRP before adding the calcium salt.
- the PRP is added to an antibiotic, such as Cloxacillin.
- the antibiotic is selected from the group formed by betalactamic antibiotics. When an antibiotic is added, it is preferably added at a concentration ten times greater than that of the plasma.
- the platelet-rich plasma (PRP) obtained is mixed with an adequate amount of a 10% by weight calcium chloride solution and is heated at 37oC, for example in bain-marie, preferably in a sterile ceramic receptacle, until gelling.
- This clotting process may take approximately between 4 and 10 minutes, depending on gel volume, among other factors.
- Platelet activation initiates the platelet degranulation process, releasing diverse growth factors, such as PDGF (platelet-derived growth factor), EGF (epidermal growth factor) and TGF (transforming growth factor) and converts the fibrinogen into fibrin, forming a cross-linking that finally gives rise to the clot.
- PDGF platelet-derived growth factor
- EGF epidermal growth factor
- TGF transforming growth factor
- the platelet gel preparation process in accordance with the third aspect of the invention, also comprises the following subsequent steps:
- the platelet gel is used to prepare a biological implant to be implanted in a soft tissue for reconstruction, augmentation or correction of abnormalities in the size and shape of said soft tissue, characterized in that said biological implant comprises a platelet gel.
- Said biological implant can be constituted by, for example, more than 50% by weight of the platelet gel, or more than 70% or more than 90%.
- said biological implant essentially consists of a platelet gel. More preferably, said biological implant consists of a platelet gel.
- the platelet gel molded as disclosed herein can be surgically implanted following the processes known in the state of the art; for example, those used for silicone gel implants, particularly in the case of a breast biological implant, it may be implanted at subglandular or subpectoral level.
- the platelet gel is used just after its clotting, in order to take maximum advantage of the benefits of releasing the growth factors that accompany the clotting process.
- the soft tissue wherein the biological implant is implanted is preferably selected from the group consisting of breast, gluteal, abdominal and facial tissue. More preferably, it is selected from breast, gluteal and abdominal tissue. Even more preferably, it is implanted in a breast.
- the platelet gel is used for the reconstruction of a breast subjected to tumorectomy.
- the PRP volume to be used to prepare the platelet gel can be calculated based on the tumour volume, which can be measured or calculated by means of the liquid displaced by the tumour itself, according to Archimedes' Principle.
- a variable correction factor (between 1.6 and 2.2) is preferably applied in order to determine the volume of platelet gel to be implanted.
- the volumetric control can be obtained by comparing the pre- and post-operative breast volumes by means of volumetric measurement using Nuclear Magnetic Resonance.
- the platelet gel is prepared from PRP obtained from a healthy allogeneic donor.
- the biological implant for soft tissue in accordance with the first aspect of the invention, comprises a platelet gel.
- Said biological implant can be constituted by, for example, more than 50% by weight of the platelet gel, or more than 70% or more than 90%.
- said biological implant essentially consists of a platelet gel. More preferably, said biological implant consists of a platelet gel.
- the biological implant according to the invention has a volume comprised between 25 and 600 cm 3 .
- the implant in accordance with the invention, can be a breast, gluteal, abdominal or facial implant, preferably a breast, gluteal or abdominal implant. More preferably, said biological implant is a breast implant.
- the present invention also provides a kit for facilitating the preparation of the biological implant, in accordance with the present invention, comprising:
- said kit also comprises a bag containing platelet-rich plasma.
- the clotting activation agent used in said kit is an aqueous solution of 10% calcium chloride.
- said kit contains at least one pre-filled syringe containing said calcium chloride solution.
- the PRP was obtained from healthy allogeneic patients following a plateletpheresis process. Plateletpheresis was carried out using the HaemoneticsTM MCS+ cell separator.
- ACD-A was used as anti-coagulant.
- the PRP obtained had a minimum platelet count of 7.5 x 10 5 - 1 x 10 6 ⁇ L.
- Plateletpheresis was carried out the day before the surgical operation.
- the volume of PRP to be used to form the platelet gel was calculated based on the volume of the tumour of each patient by means of the volume displaced by the tumorectomy piece immersed in saline solution in a test tube. A correction factor of approximately 1.6 was then applied.
- the mixture was heated at 37oC in bain-marie in a sterile ceramic receptacle until it gelled.
- the clotting process took approximately between 4 and 10 minutes.
- the process was accelerated by adding human thrombin.
- a sample was taken from 19 patients, four forming the control group and 15 the cases under study.
- the patients were women with unilateral breast neoplasia who were candidates for preserving treatment.
- the patients of the control group were subjected to tumorectomy in a breast without any kind of volumetric reconstruction.
- Example 4 Comparative analysis of patients subjected to a breast neoplasia operation with and without volume reconstruction using platelet gel
- Table 1 shows the tumorectomy volumes and the platelet gel volume added for breast reconstruction, and reflects the results of the post-operative volumetric appearance in relation to the pre-operative volumetric appearance at different times.
- the criterion used to evaluate the results was a subjective criterion based on two observers. Therefore, it was defined as:
- Table 2 shows the tumorectomy volumes of patients subjected to a breast neoplasia operation without volume reconstruction using platelet gel as well as the results of the post-operative appearance in relation to pre-operative appearance at different times.
- the data shown in Table 1 reveal that the post-operative volumetric appearance in relation to the pre-operative appearance in patients subjected to a breast neoplasia operation with volume reconstruction using platelet gel remained satisfactory in most of the patients throughout the observed time periods.
- the data shown in Table 2 reveal that, in the case of patients not subjected to volume reconstruction using platelet gel, even though in some cases the appearance of the breast was apparently satisfactory immediately after the operation, one month after the operation the appearance of the breast was no longer satisfactory in most of them.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Transplantation (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Materials For Medical Uses (AREA)
- Prostheses (AREA)
Description
- The present invention relates to the field of reconstruction and augmentation of soft tissue, particularly breast tissue.
- Growing awareness of breast cancer, along with improved diagnosis techniques, allow to get diagnosis at very early stages. Thus, an increasing number of non-invasive techniques that avoid mastectomy and are limited to the excision of the tumour (tumorectomy) with wide resection margins can be applied. In spite of this, even in these cases of minimally invasive surgery, the occurrence of aesthetical defects due to the cavity left by the tumorectomy, which is an empty space that does not maintain the volume of the organic structure, is frequent. Additionally, there are still several situations wherein it is not possible to avoid mastectomy, for example when the tumour has a disproportionate size with respect to breast volume or in the case of unilateral multicentric tumours.
- Synthetic breast implants or autologous reconstruction (i.e. reconstruction using the patient's own tissue) are used for the reconstruction of breasts subjected to tumorectomy or mastectomy or for breast augmentation.
- The main types of artificial implants consist of a silicone capsule filled with silicone gel or saline solution. Combined implants have also been disclosed in the literature, such as that disclosed in
EP-A-797460 - In autologous reconstructions, abdominal adipose skin and tissue and part of the straight abdominal muscles are normally used. Alternatively, latissimus dorsi musculocutaneous flap tissue has also been used.
- In order to fill up tumorectomy cavities, other techniques such as oncoplastic techniques are also used, which are aimed at improving the patient's appearance by remodelling the remaining gland itself (remaining gland technique).
- Both autologous reconstructions and artificial implants have several drawbacks. On one hand, the problems associated with said artificial implants include deflation, infection, capsular contracture, displacement and formation of calcium deposits. On the other hand, the aforementioned autologous implants provide generally acceptable aesthetical results but with a not inconsiderable morbidity. Additionally, the scars that appear on the donor site and the potential increase for complications must also be taken into account (Cleveland Clinic Journal of Drug 2008; 75(1): S17-S23). A high number of resorptions have also been disclosed.
- The use of silicone implants in other areas, such as the glutei, has also been disclosed.
- Platelets play a basic role in the wound repair process, regardless of their aetiology. When a wound occurs, the platelets become activated and release diverse growth factors, such as PDGF (platelet-derived growth factor), EFT (epidermal growth factor) and TGF (transforming growth factor), which converts fibrinogen into fibrin, forming a cross-linking that finally gives rise to a clot.
- Activation of a platelet concentrate (PRP) by adding a clotting cascade activator, such as an excess of calcium ions (calcium chloride), thrombin, batroxobin, etc., gives rise to the formation of a gelatinous substance known as platelet gel.
- At present, platelet gel is widely used in dental and oral and maxillofacial surgery, where it is used basically for bone implantation and regeneration. It is also applied to chronic wounds, ulcers and soft tissues (such as tendons and ligaments). A layer is generally spread over the wound bed to aid healing. Its use in facial plastic surgery and breast augmentation and reduction operations as a sealant and haemostatic agent has been disclosed, where it reduced the need for drainage and compressive bandaging as well as the incidence of complications (Acta Dermatoven APA Vol. 16, 207, No. 4).
- However, the results of a double-blind randomized trial to evaluate the topical application of autologous platelet gel in reduction mammoplasty did not reveal any significant improvement due to the use of the gel (Plastic and Reconstructive Surgery (2007), 119(4), 1159-1166).
- Different methods and kits for preparing platelet gel have been disclosed, for example, in
U.S. patent number US6942880 . This patent, among several embodiments, mentions that optionally the autologous platelet gel can be moulded into a geometric, rectangular, conical or roller shape to temporarily fill, by way of a plug, cavities due to dental extraction or bone cavities. Although it does not explicitly indicate what can be considered a temporary filling, it does indicate that, for example, another bioadhesive sealant formed by clotting of fibrinogen with thrombin is reabsorbed in just ten days. In the only example provided, the gel is prepared from just 6 cm3 of PRP. - The problem to be solved by the present invention is the provision of a biological implant to be implanted in a soft tissue, preferably a breast, for reconstruction or augmentation of the volume of said tissue, that will overcome the drawbacks of the state of the art.
- The solution is based on the fact that the present inventors unexpectedly found that the use of conveniently moulded platelet gel allows the re-establishment of soft tissue volume over time (see example 3). In particular, the inventors verified this upon introduction into a cavity produced by tumorectomy in a breast, obtaining good results even using large volumes, for example 250 cm3, so that it can be used by way of a biological implant such as a breast implant.
- The present inventors have achieved the volumetric substitution of removed tissue using the platelet gel, favoring internal scarring and improving the aesthetical result without increasing surgical morbidity, as well as augmenting breast volume.
- Therefore, the disclosure relates to the use of a platelet gel for preparing a a biological implant to be implanted in a soft tissue for reconstruction, augmentation or correction of abnormalities in the size and shape of said soft tissue, characterized in that said biological implant comprises a platelet gel.
- Alternatively, this aspect of the disclosure can be worded as platelet gel for use as a biological implant to be implanted in a soft tissue for reconstruction, augmentation or correction of abnormalities in the size and shape of said soft tissue.
- The first aspect of the invention relates to a biological implant for soft tissue comprising a platelet gel according to the set of claims
- A second aspect of the invention relates to a kit for preparing a biological implant according to the present invention, comprising
- at least one mould in the shape of a round concave receptacle with a volume comprised between 75 and 700 cm3,
- at least one syringe,
- one clotting activator, and
- optionally, one drug.
- A third aspect of the invention relates to a process for preparing the biological implant, in accordance with the present invention, comprising the following steps:
- (i) Combining a platelet-rich plasma with a clotting activator and, optionally, a drug,
- (ii) Heating the mixture in a mould in the shape of a round concave receptacle with a volume comprised between 75 and 700 cm3 at a temperature from 30ºC to 40ºC, in order to achieve the gelling of said mixture.
- A fourth aspect of the invention relates to a biological implant for soft tissue for use according to the set of claims.
- The use of the platelet gel, in accordance with the disclosure, represents a number of advantages:
- It avoids the use of artificial materials and the risks deriving from its use, such as infections, diffusion or displacements;
- It enhances the restructuration of the remaining healthy breast tissue, taking advantage of the fact that the substances released by the platelets, such as growth factors, initiate and accelerate tissue repair and regeneration.
- Additionally, the use of platelet gel, as disclosed herein, is particularly advantageous in tumorectomy and mastectomy operations:
- It allows remodeling the breast during the same surgical operation as the mastectomy and/or subcutaneous mastectomy, avoiding other oncoplastic techniques which require a subsequent or more complex surgical operation and the potential complications thereof;
- It minimizes the anti-aesthetic retractions susceptible from more complex surgical operations;
- It can facilitate selective radiotherapy on distending the residual cavity;
- The fact that the gel can be prepared in situ allows to have greater flexibility for preparing any desired volume, based on the tumour volume calculated after extraction, advantageously for tumorectomies, as opposed to artificial silicone implants of a determined size.
- It allows the application of a preserving surgical treatment (tumorectomy) to larger size tumours that were previously only candidates for mastectomy due to being disproportionate to the size of the breast;
- It allows the application of the preserving surgical treatment (tumorectomy) to unilateral multifocal tumours that were previously only candidates for mastectomy due to aesthetic reasons.
- It allows to improve the identification of relapses, preventing differentiation of residual scars;
- It does not alter the monitoring protocol by means of mammography, ecography or NMR (Nuclear Magnetic Resonance);
- It improves the appearance of the patient, allowing a faster incorporation into the job market;
- It reduces the costs of the reconstruction processes required for this type of surgery.
- Platelet gel is obtained from platelet-rich plasma (PRP) whereto a clotting process-activating substance (for example, calcium chloride) is added.
- PRP, as used herein, is understood to be a concentration of platelets greater than the concentration in peripheral blood suspended in a plasma solution. PRP typically has a minimum platelet count of 7.5 x 105 - 1 x 106 per µL.
- Biological implant, as used herein, is understood to be a product of substantially biological origin for the replacement or augmentation of a missing or imperfect part of the body.
- The platelet dosage required for preparing the platelet gel can be obtained by means of plateletpheresis. Plateletpheresis comprises extraction and separation of blood into its different components by centrifugation at different speeds for the purpose of obtaining platelet-rich plasma (PRP).
- PRP can be obtained from the same patient whom the gel (autologous platelet gel) will be implanted or from a healthy allogeneic donor. In the event that the gel will be used for the reconstruction of a breast already subjected to tumorectomy or mastectomy, the platelets are obtained from a healthy allogeneic donor, optionally related to the patient.
- Plateletpheresis can be carried out, for example, using the Haemonetics™ MCS+ cell separator or Medtronic Inc.'s Magellan™ Autologous Platelet Separation System.
- During the plateletpheresis process an anticoagulant is added preferably based on citric acid, such as ACD-A (citric acid, sodium citrate and dextrose).
- In general, PRP is required to have a minimum platelet count of 7.5 x 105 - 1 x 106 per µL.
- When the PRP is obtained from an allogeneic donor it is preferably treated by irradiation to deactivate any existing viral material or residual leukocyte. This treatment can be carried out during any stage of the gel preparation process.
- The PRP is activated by adding a clotting activator, which is understood to be a substance capable of restoring anti-clotting activity, such as calcium chloride or other calcium salt which acts in a similar way, such as calcium gluconate or calcium carbonate. Preferably, calcium chloride is added as a 105 by weight aqueous solution.
- Other clotting activators can also be used, including thrombin or batroxobin, by heating the mixture at 37ºC.
- The platelet gel can also be obtained by means of the processes disclosed in literature, such as those disclosed in
EP-B-1239895 , which use batroxobin instead of thrombin. - The PRP volume to be used is determined based on the final volume to be augmented or restored. Preferably, a correction factor comprised between 1.6 and 2.2 is applied. The mixture is allowed to clot in a sterilised mould having adequate dimensions. The mould can be made, for example, of ceramic, plastic, silicone glass or stainless steel. Preferably, it is allowed to clot in a sterile porcelain or stainless steel receptacle. More preferably, a porcelain mould is used.
- The shape of the mould in general is such that the resulting gel adopts the desired shape of the implant. The mould is preferably formed in the shape of a round concave receptacle with a volume comprised between 75 and 700 cm3. In one embodiment, the mould has a substantially semispherical shape. In a preferred embodiment, the shape of the mould is such that the resulting gel takes the form of a breast implant with different volumes. In accordance with the invention, the platelet gel for implantation has a volume comprised between 25 and 600 cm3.
- Formation of the gel is fast, generally being formed in less than fifteen minutes.
- The platelet gel can optionally be used to release drugs such as antibiotics, anti-bacterials, analgesics, anti-inflammatories, anti-cancer compounds and tumoricidal or tumor static compounds. These compounds can be added to the PRP before adding the calcium salt. In one embodiment of the invention, the PRP is added to an antibiotic, such as Cloxacillin. Preferably, the antibiotic is selected from the group formed by betalactamic antibiotics. When an antibiotic is added, it is preferably added at a concentration ten times greater than that of the plasma.
- In a preferred embodiment, the platelet-rich plasma (PRP) obtained is mixed with an adequate amount of a 10% by weight calcium chloride solution and is heated at 37ºC, for example in bain-marie, preferably in a sterile ceramic receptacle, until gelling. This clotting process may take approximately between 4 and 10 minutes, depending on gel volume, among other factors.
- Platelet activation initiates the platelet degranulation process, releasing diverse growth factors, such as PDGF (platelet-derived growth factor), EGF (epidermal growth factor) and TGF (transforming growth factor) and converts the fibrinogen into fibrin, forming a cross-linking that finally gives rise to the clot.
- In a preferred embodiment of the invention, the platelet gel preparation process, in accordance with the third aspect of the invention, also comprises the following subsequent steps:
- Cooling the gelled mixture, preferably at room temperature, to give rise to the formation of a liquid phase differentiated from the gel phase, and
- Isolation of the gel phase obtained in the previous step.
- As disclosed herein, the platelet gel is used to prepare a biological implant to be implanted in a soft tissue for reconstruction, augmentation or correction of abnormalities in the size and shape of said soft tissue, characterized in that said biological implant comprises a platelet gel. Said biological implant can be constituted by, for example, more than 50% by weight of the platelet gel, or more than 70% or more than 90%. Preferably, said biological implant essentially consists of a platelet gel. More preferably, said biological implant consists of a platelet gel.
- The platelet gel molded as disclosed herein can be surgically implanted following the processes known in the state of the art; for example, those used for silicone gel implants, particularly in the case of a breast biological implant, it may be implanted at subglandular or subpectoral level.
- Preferably, the platelet gel is used just after its clotting, in order to take maximum advantage of the benefits of releasing the growth factors that accompany the clotting process.
- The soft tissue wherein the biological implant is implanted, in accordance with the invention, is preferably selected from the group consisting of breast, gluteal, abdominal and facial tissue. More preferably, it is selected from breast, gluteal and abdominal tissue. Even more preferably, it is implanted in a breast.
- Preferably, the platelet gel is used for the reconstruction of a breast subjected to tumorectomy. In this case, the PRP volume to be used to prepare the platelet gel can be calculated based on the tumour volume, which can be measured or calculated by means of the liquid displaced by the tumour itself, according to Archimedes' Principle. After calculating the tumour volume, a variable correction factor (between 1.6 and 2.2) is preferably applied in order to determine the volume of platelet gel to be implanted. The volumetric control can be obtained by comparing the pre- and post-operative breast volumes by means of volumetric measurement using Nuclear Magnetic Resonance.
- When the patient has been subjected to tumorectomy or mastectomy, the platelet gel is prepared from PRP obtained from a healthy allogeneic donor.
- The biological implant for soft tissue, in accordance with the first aspect of the invention, comprises a platelet gel. Said biological implant can be constituted by, for example, more than 50% by weight of the platelet gel, or more than 70% or more than 90%. Preferably, said biological implant essentially consists of a platelet gel. More preferably, said biological implant consists of a platelet gel.
- The biological implant according to the invention has a volume comprised between 25 and 600 cm3.
- The implant, in accordance with the invention, can be a breast, gluteal, abdominal or facial implant, preferably a breast, gluteal or abdominal implant. More preferably, said biological implant is a breast implant.
- The present invention also provides a kit for facilitating the preparation of the biological implant, in accordance with the present invention, comprising:
- a mould in the shape of a round concave receptacle with a volume comprised between 75 and 700 cm3,
- at least one syringe
- one clotting activator, and
- optionally, a drug.
- In a preferred embodiment, said kit also comprises a bag containing platelet-rich plasma. Preferably, the clotting activation agent used in said kit is an aqueous solution of 10% calcium chloride. In one embodiment, said kit contains at least one pre-filled syringe containing said calcium chloride solution.
- Several examples of the invention are shown below in an illustrative non-limiting way.
- The PRP was obtained from healthy allogeneic patients following a plateletpheresis process. Plateletpheresis was carried out using the Haemonetics™ MCS+ cell separator.
- ACD-A was used as anti-coagulant.
- The PRP obtained had a minimum platelet count of 7.5 x 105 - 1 x 106 µL.
- Plateletpheresis was carried out the day before the surgical operation.
- The volume of PRP to be used to form the platelet gel was calculated based on the volume of the tumour of each patient by means of the volume displaced by the tumorectomy piece immersed in saline solution in a test tube. A correction factor of approximately 1.6 was then applied.
- The PRP volumes used for each patient under study are shown in Table 1.
- In each case, a 10% by volume of an aqueous solution of 10% by weight calcium chloride was added to the volume of platelet-rich plasma (PRP) and mixed.
- The mixture was heated at 37ºC in bain-marie in a sterile ceramic receptacle until it gelled.
- In general, the clotting process took approximately between 4 and 10 minutes.
- In some cases, the process was accelerated by adding human thrombin.
- A sample was taken from 19 patients, four forming the control group and 15 the cases under study.
- The patients were women with unilateral breast neoplasia who were candidates for preserving treatment.
- Those patients who fulfilled any of the following exclusion criteria were excluded: treatments with anticoagulants, primary clotting and/or scarring alteration and breast infection at the time of the surgical operation.
- In the fifteen cases under study, the patients were subjected to tumorectomy in a breast with wide margins and immediate volume reconstruction using platelet gel, obtained in accordance with Example 2.
- The patients of the control group were subjected to tumorectomy in a breast without any kind of volumetric reconstruction.
- In order to evaluate the result of the use of the platelet gel for breast reconstruction in patients subjected to a breast neoplasia operation, they were given a questionnaire to evaluate their degree of satisfaction and digital photographs were taken at different times (pre-operative, immediate post-operative and after one, three months, six months and one year).
- Table 1 shows the tumorectomy volumes and the platelet gel volume added for breast reconstruction, and reflects the results of the post-operative volumetric appearance in relation to the pre-operative volumetric appearance at different times.
Table 1.- PATIENT TUMOUR VOLUME (cm3) PRP VOLUME (cm3) POST-OPERATIVE APPEARANCE IMMEDIATE 1 week 1 month 3 months 01 90 110 VG VG VG G 02 40 60 VG VG VG VG 03 30 45 VG VG VG VG 04 50 40 VG VG VG VG 05 30 50 VG VG VG VG 06 33 40 VG VG VG 07 70 105 VG VG VG 08 75 105 VG VG G 09 44 104 VG VG A 10 30 80 VG VG VG 11 80 140 VG VG VG 12 70 100 VG VG VG 13 50 80 VG VG B 14 45 60 VG VG VG 15 160 250 VG VG VG VG= Very Good, G= Good, A= Average, B= Bad, VB= Very Bad - The criterion used to evaluate the results was a subjective criterion based on two observers. Therefore, it was defined as:
- Very Good: identical or practically identical aesthetic result to that before the operation,
- Good: if the volume was preserved,
- Average: if any morphometrical deficiency was observed, the perimeter was not exactly the same but rather somewhat smaller,
- Bad: if evident excavation was observed,
- Very Bad: if retraction was observed.
- Table 2 shows the tumorectomy volumes of patients subjected to a breast neoplasia operation without volume reconstruction using platelet gel as well as the results of the post-operative appearance in relation to pre-operative appearance at different times.
Table 2.- PATIENT TUMOUR VOLUME (cm3) POST-OPERATIVE APPEARANCE IMMEDIATE 1 week 1 month 3 months 6 months 01 40 VG VG G A 02 70 G A B B 03 30 VG G A B 04 50 G G B VG= Very Good, G= Good, A= Average, B= Bad, VB= Very Bad - The data shown in Table 1 reveal that the post-operative volumetric appearance in relation to the pre-operative appearance in patients subjected to a breast neoplasia operation with volume reconstruction using platelet gel remained satisfactory in most of the patients throughout the observed time periods. On the contrary, the data shown in Table 2 reveal that, in the case of patients not subjected to volume reconstruction using platelet gel, even though in some cases the appearance of the breast was apparently satisfactory immediately after the operation, one month after the operation the appearance of the breast was no longer satisfactory in most of them.
- The photographs taken of the patients after the surgical operation show that, in most of the group of patients under study subjected to a breast neoplasia operation with volume reconstruction using platelet gel, after one month and, in five of them, several months after the operation, no deformation of the breast neither in the area surrounding the scar was observed, which had a clean appearance and completely smooth skin. While in the case of the control group, just one month after the operation the scar became retracted and sunken into the cavity left by the tumour, producing anti-aesthetic deformations.
- With regard to the post-operative monitoring by radiological image (ecography, mammography and magnetic resonance), in one patient the appearance of macrocalcifications in the implant bed was observed which, on having a circumscribed arrangement, allows radiological monitoring thereof without considering differential diagnosis with other tumour sources.
Claims (15)
- Biological implant for soft tissue which comprises a platelet gel, wherein said platelet gel has a volume comprised between 25 and 600 cm3.
- Biological implant for soft tissue, according to claim 1, wherein said platelet gel is present in more than 50% by weight in said biological implant.
- Biological implant for soft tissue, according to claim 1 or 2, further comprising at least one active ingredient selected from the group consisting of: antibiotics, anti-bacterials, analgesics, anti-inflammatories, anti-cancer compounds and tumoricidal and tumour static compounds.
- Biological implant for soft tissue, according to claim 1, which essentially consists of a platelet gel, wherein said platelet gel has a volume comprised between 25 and 600 cm3.
- Biological implant for soft tissue, according to any of claims 1 to 4, wherein said soft tissue is selected from the group consisting of breast, abdomen and gluteous.
- Biological implant for soft tissue, according to claim 5, wherein said soft tissue is breast.
- Biological implant for soft tissue, according to any of claims 1 to 6, wherein said platelet gel is prepared from platelet-rich plasma from a healthy allogeneic donor.
- Biological implant for soft tissue, according to claim 7, wherein said platelet gel is prepared from a volume of platelet-rich plasma comprised between 1.6 and 2.2 times the tumour volume.
- Biological implant for soft tissue, according to claim 7, wherein said platelet gel is obtainable from said platelet-rich plasma clotted by adding calcium chloride and treatment at 37ºC.
- Biological implant for soft tissue, according to any of claims 1 to 9, for use in the reconstruction, augmentation or correction of abnormalities in the size and shape of said soft tissue.
- Biological implant for soft tissue, according to claim 10, for use in the reconstruction of a breast which has been previously subjected to tumorectomy.
- Kit for preparing a biological implant, according to any of claims 1 to 9, comprising:- at least one mould in the shape of a round concave receptacle with a volume comprised between 75 and 700 cm3,- at least one syringe,- a clotting activator, and- optionally, a drug.
- Kit, according to claim 12, which further comprises a bag containing platelet-rich plasma.
- Process for preparing a biological implant, according to any of claims 1 to 9, which comprises the following steps:(i) Combining platelet-rich plasma with a clotting activator and, optionally, a drug,(ii) Heating the mixture in a mould in the shape of a round concave receptacle with a volume comprised between 75 and 700 cm3 at a temperature from 30ºC to 40ºC, in order to achieve the gelling of said mixture.
- Process, according to claim 14, further comprising the following subsequent steps:(iii) Cooling the gelled mixture obtained in step (ii) to give rise to the formation of a liquid phase differentiated from the gel phase, and(iv) Isolation of the gel phase obtained in step (iii).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES200901433 | 2009-06-11 | ||
PCT/EP2010/058226 WO2010142784A2 (en) | 2009-06-11 | 2010-06-11 | Use of gelled prp (platelet gel) for volumetric breast reconstruction |
Publications (2)
Publication Number | Publication Date |
---|---|
EP2470229A2 EP2470229A2 (en) | 2012-07-04 |
EP2470229B1 true EP2470229B1 (en) | 2017-08-23 |
Family
ID=42711687
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP10722715.9A Active EP2470229B1 (en) | 2009-06-11 | 2010-06-11 | Use of gelled prp (platelet gel) for volumetric breast reconstruction |
Country Status (4)
Country | Link |
---|---|
US (1) | US9199007B2 (en) |
EP (1) | EP2470229B1 (en) |
ES (1) | ES2648090T3 (en) |
WO (1) | WO2010142784A2 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2527967B1 (en) * | 2013-08-01 | 2015-12-28 | Biotechnology Institute, I Mas D, S.L. | Formulation of a blood composition rich in platelets and / or growth factors, with gelled proteins and method of preparation thereof |
EP3416694A4 (en) | 2016-02-17 | 2019-10-30 | The Governing Council of the University of Toronto | Biodegradable soft tissue filler |
ES2778798B2 (en) * | 2019-02-11 | 2021-10-13 | Biotechnology Inst I Mas D Sl | FORMULATION OR TISSUE ADHESIVE OBTAINED FROM A BLOOD COMPOSITION CONTAINING PLATELETS, AND METHOD OF PREPARING SUCH FORMULATION |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003017913A1 (en) * | 2001-08-27 | 2003-03-06 | The Cleveland Clinic Foundation | Compositions, methods and apparatus for surgical procedures |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5752974A (en) * | 1995-12-18 | 1998-05-19 | Collagen Corporation | Injectable or implantable biomaterials for filling or blocking lumens and voids of the body |
ITAL990010U1 (en) | 1999-12-14 | 2001-06-14 | Maria Cristina Sacchi | NEW LABORATORY METHOD FOR PREPARING GEL AND PLATE MEMBRANES OBTAINED FROM THE PLATE CONCENTRATE. |
US6942880B1 (en) | 2001-04-09 | 2005-09-13 | Medtronic, Inc. | Autologous platelet gel having beneficial geometric shapes and methods of making the same |
ITRM20040638A1 (en) * | 2004-12-24 | 2005-03-24 | Advance Holdings Ltd | SEMISINTETIC PIASTRINIC GEL AND METHOD FOR ITS PREPARATION. |
US20070014784A1 (en) * | 2005-06-23 | 2007-01-18 | Medtronic Vascular, Inc. | Methods and Systems for Treating Injured Cardiac Tissue |
-
2010
- 2010-06-11 WO PCT/EP2010/058226 patent/WO2010142784A2/en active Application Filing
- 2010-06-11 EP EP10722715.9A patent/EP2470229B1/en active Active
- 2010-06-11 US US13/377,293 patent/US9199007B2/en active Active
- 2010-06-11 ES ES10722715.9T patent/ES2648090T3/en active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003017913A1 (en) * | 2001-08-27 | 2003-03-06 | The Cleveland Clinic Foundation | Compositions, methods and apparatus for surgical procedures |
Also Published As
Publication number | Publication date |
---|---|
ES2648090T3 (en) | 2017-12-28 |
US20120087989A1 (en) | 2012-04-12 |
US9199007B2 (en) | 2015-12-01 |
WO2010142784A3 (en) | 2011-04-07 |
EP2470229A2 (en) | 2012-07-04 |
WO2010142784A2 (en) | 2010-12-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11992580B2 (en) | Method of soft tissue augmentation | |
JP6491199B2 (en) | Hyaluronic acid cross-linking method; injection hydrogel preparation method; resulting hydrogel; use of the resulting hydrogel | |
CN112220802A (en) | Process for preparing wound repair agent composition, tube and device | |
RU2660561C2 (en) | Use of ex-vivo adipose tissue-derived stem cells for cosmetic breast lipofilling or for facial lipofilling and/or rejuvenation | |
O'Halloran et al. | Recent advances and future directions in postmastectomy breast reconstruction | |
RU106528U1 (en) | CELLULAR IMPLANT FOR REPAIR OF SKIN DEFECTS | |
KR101710615B1 (en) | Dermal matrix for transplantation having improved survival rate and method for preparing thereof | |
BR112020015616B1 (en) | BIOINK COMPOSITION FOR DERMIS REGENERATION SHEET, METHOD FOR MANUFACTURING CUSTOM DERMIS REGENERATION SHEET USING THE SAME AND CUSTOM DERMIS REGENERATION SHEET MANUFACTURED USING THE MANUFACTURING METHOD | |
AU2020267589B2 (en) | Tissue derived porous matrices and methods for making and using same | |
EP2470229B1 (en) | Use of gelled prp (platelet gel) for volumetric breast reconstruction | |
JP2006528672A5 (en) | ||
CN117797172B (en) | Preparation method of anti-inflammatory, hemostatic and healing-promoting combination | |
CN111228216B (en) | Pharmaceutical carrier combinations, pharmaceutical compositions, uses thereof, methods of making the same, and methods of using the same | |
Victorovich | Application of finely granulated titanium nickelide in surgical practice | |
RU34865U1 (en) | The structure of the material for implantation in the larynx | |
Jegorov et al. | Wichterle hydron for breast augmentation–case reports and brief review | |
CN114146230A (en) | Composition for forming filling hydrogel after tooth extraction and application thereof | |
Kaufman | Reawakening the most hard-to-heal chronic wounds: long-term outcomes of a randomised, controlled trial with active negatively charged microsphere (NCAA) technology. | |
Guideline | Skin Substitutes for Wound Care AHM | |
Tousson et al. | Use of lipomodelling in breast-reconstructive surgery | |
Hindin et al. | Electrospun soy protein scaffolds enhance skin regeneration in a rat wound model | |
Hsieh et al. | USING POROUS POLYETHYLENE IMPLANT FOR MAXILLOFACIAL BONY RECONSTRUCTION—A GENERAL INTRODUCTION AND CASE REPORT OF A COMPLICATION | |
EA028141B1 (en) | Method for producing biodegradable, biocompatible tissue-engineered sheets using cultured fibroblasts |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20120426 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR |
|
DAX | Request for extension of the european patent (deleted) | ||
17Q | First examination report despatched |
Effective date: 20140804 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
GRAJ | Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted |
Free format text: ORIGINAL CODE: EPIDOSDIGR1 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: BANC DE SANG I TEIXITS Owner name: UNIVERSITAT AUTONOMA DE BARCELONA Owner name: FUNDACIO INSTITUT EN CIENCIES DE LA SALUT GERMANS |
|
INTG | Intention to grant announced |
Effective date: 20170207 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: UNIVERSITAT AUTONOMA DE BARCELONA Owner name: FUNDACIO INSTITUT EN CIENCIES DE LA SALUT GERMANS Owner name: BANC DE SANG I TEIXITS |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE PATENT HAS BEEN GRANTED |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: REF Ref document number: 920647 Country of ref document: AT Kind code of ref document: T Effective date: 20170915 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602010044607 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2648090 Country of ref document: ES Kind code of ref document: T3 Effective date: 20171228 Ref country code: NL Ref legal event code: MP Effective date: 20170823 |
|
REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG4D |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK05 Ref document number: 920647 Country of ref document: AT Kind code of ref document: T Effective date: 20170823 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170823 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170823 Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170823 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170823 Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170823 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170823 Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20171123 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170823 Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20171123 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20171223 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170823 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20171124 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170823 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170823 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170823 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602010044607 Country of ref document: DE |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170823 Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170823 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170823 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed |
Effective date: 20180524 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170823 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20180611 |
|
REG | Reference to a national code |
Ref country code: BE Ref legal event code: MM Effective date: 20180630 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: MM4A |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20180611 Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170823 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20180630 Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20180611 Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20180611 Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20180630 Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20180630 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20180630 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20180611 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170823 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20100611 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170823 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170823 Ref country code: MK Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20170823 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: AL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170823 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20230620 Year of fee payment: 14 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IT Payment date: 20230630 Year of fee payment: 14 Ref country code: ES Payment date: 20230719 Year of fee payment: 14 |
|
P01 | Opt-out of the competence of the unified patent court (upc) registered |
Effective date: 20231011 |